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Patients with HIV/AIDS have a higher risk of developing aggressive B-cell lymphomas, such as diﬀuse large B-cell lymphoma
(DLBCL). Lymphomas are rather heterogeneous in nature and in a few cases can switch their genetic or immunohistochemical
phenotype, transform into other lymphomas or carry more than one malignant clone. In this report, we present the case of a
47-year-old man with HIV infection who was diagnosed with an apparent low-risk, early-stage DLBCL, but became refractory to
therapywhileundergoingtreatmentwithrituximab-containingchemotherapy.Wepostulatethatthedevelopmentofhisrefractory
disease occurred in the context of an immunohistochemical switch or the surge of a clone refractory to therapy. This phenomenon
was not associated with a superinfection with EBV or HHV-8.
A 47-year-old HIV-positive male presented complaining of
one-week course of right arm pain and swelling within the
rightaxillaryarea.Hedeniedfevers,nightsweats,weightloss,
ortraumatohisarm.Hispastmedicalhistorywassigniﬁcant
for HIV diagnosed 10 years earlier with a recent CD4 count
of 456 cells/mm3. He worked as a cook, lived with his
male partner, was on no antiretroviral therapy (ART), drank
rarely, and did not engage in the use of illicit drugs. Physical
exam revealed a 4.5-cm right axillary mass and a palpable
mass within the right pectoralis region that was tender
on palpation. There was no hepatosplenomegaly and no
other abnormalities on physical examination. Laboratories
revealed a white blood cell count (WBC) of 5.7 × 109/L
with a normal diﬀerential, hemoglobin of 14.3g/dL, platelet
count of 166×109/L, and LDH of 265IU/L. A computerized
tomography (CT) scan of the chest showed a markedly
enlarged right pectoralis minor muscle with an adjacent
enlarged right axillary lymph node measuring 5.2 × 3.0cm.
CT scans of the abdomen and pelvis were unremarkable.
An excisional biopsy of a right axillary lymph node
was performed. On gross pathological examination, large
atypical cells were seen with features of centroblasts
and immunoblasts along with numerous mitotic ﬁgures.
Immunohistochemically, the large cells are positive for
CD20, PAX5, and bcl-2, weakly positive for bcl-6, CD30,
and negative for CD3, CD5, CD10 and MUM-1 (Figure 1).
A bone marrow biopsy and aspirate showed normocel-
lularity and trilineage hematopoiesis with no evidence of
lymphoma. Patient was diagnosed with stage IIA diﬀuse
large B-cell lymphoma of a germinal center (GC) subtype.
His International Prognostic Index (IPI) score was 1. He
was initiated on chemotherapy with R-CHOP (rituximab,
cyclophosphamide, doxorubicin, vincristine, and oral pred-
nisone)every3weeks.HisLDHwasnormalizedaftertheﬁrst
cycle of chemotherapy and after the second cycle a CT scan
of the chest showed signiﬁcant decrease in size of the prior
lymphadenopathy.
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Figure 1: CD20-positive diﬀuse large B-cell lymphoma with a germinal center immunophenotypical proﬁle (initial excisional biopsy).
progressive right axillary lymphadenopathy, and right upper
extremity, chest wall, and scrotal edema. A PET/CT scan
showed interval decrease in the size of initial bulky chest
and axillary adenopathy but revealed extensive right supra-
clavicular, axillary, and right lateral wall FDG-avid disease
as well as FDG-avid cutaneous and subcutaneous nodular
thickening of the right anterolateral chest wall. The patient
was referred to a surgeon for a skin and lymph node biopsy.
While awaiting results of the biopsies, he developed left-
sided facial numbness and presented to the emergency room
where a noncontrast cat scan of his head was negative, and











Figure 2: CD20-negative diﬀuse large B-cell lymphoma with a nongerminal center immunophenotypical proﬁle (second excisional biopsy).
showed a protein of 87mg/dl (normal range 15–45mg/dl)
and glucose of 58mg/dl (normal range 38–85mg/dl) as well
as rare atypical cells felt to be consistent with lymphoma. An
MRI of the brain with gadolinium demonstrated abnormal
soft tissue enhancement of the left Meckel’s cave and right
internal auditory canal, highly suspicious for lymphomatous
meningitis. Intrathecal methotrexate was initiated. His left
facial weakness progressed and the patient developed ptosis
and blurry vision of the left eye, which was resolved after the
second injection of intrathecal methotrexate.4 Pathology Research International
Pathological examination of his biopsy showed cells with
large nuclei and open chromatin, one to multiple conspicu-
ousnucleoli,andscantcytoplasm.Therewerealsonumerous
apoptotic cells. By immunohistochemistry, this neoplastic
lymphoid population was negative for CD20, bcl-6, and
CD10 but uniformly positive for CD45, CD43, CD30, and
MUM-1 (Figure 2), and had a variable PAX-5 and bcl-2
positivity. These neoplastic B cells had a high proliferation
rate (MIB-1 90%–100%) but were negative for CD3, CD4,
CD8, cyclin-D1, CD15, and anaplastic lymphoma kinase
(ALK-1). An anti-EBV latent membrane protein antibody
was negative. Molecular studies were also performed and
detected the presence of IgH gene rearrangement, however,
there were no T-cell receptor gene rearrangements, no bcl-2
translocation, and no EBV DNA sequences detected. FISH
studies were negative for the presence of MYC rearrange-
ments. He was diagnosed with relapsed stage IV DLBCL
of a nongerminal center (NGC) immunophenotype. An
Ommayareservoirwasplacedforbiweeklymethotrexateand
a port-a-cath placed for rituximab with infusional EPOCH
(etoposide, vincristine, doxorubicin, cyclophosphamide, and
prednisone). As his neurological symptoms, rash, and lym-
phadenopathy had improved, the patient was discharged
home and returned to clinic for biweekly intrathecal
methotrexate.Threeweekslater,thepatientwasadmittedfor
his second cycle, during which he developed worsening pain
and swelling on his right side. The patient and his partner
decided to pursue palliative radiation to his right chest wall.
Shortly thereafter, the patient developed a sharp decline in
his mental status. A head CT scan showed a suprasellar mass
and CNS extension of his DLBCL at which point the patient
and his partner elected to pursue hospice care.
DLBCL is the most common lymphoma variant seen
in the general population, accounting for approximately
25%–30% of all cases [1]. Individuals infected with HIV
are at a higher risk of developing DLBCL than the general
population. With the advent of HAART, the absolute inci-
dence of DLBCL in HIV-positive individuals seems to have
decreased [2]; however, the relative incidence has probably
increased due to deeper impact on the incidence of other
common malignancies such as Kaposi sarcoma [3]. The
treatment of DLBCL in HIV-infected individuals consists
on combination chemotherapy; RCHOP is the standard of
care for immunocompetent patients with DLBCL [4, 5]. A
phase III trial showed no survival beneﬁt in HIV-positive
DLBCL patients with the addition of rituximab to CHOP
[6]; however, with better prophylactic schemes, HIV-positive
patients with a CD4 count >100 cells/mm3 can derive beneﬁt
from the addition of rituximab [7].
There are few studies showing phenotypical and his-
tological changes in patients with lymphomas after expo-
sure to rituximab [8]. Rituximab is a chimeric anti-CD20
monoclonal antibody; hence, it is not surprising for it to
downregulateCD20expressionwithinthetumoralcells.This
eﬀect is reﬂected by the CD20negativity seen in the second
sample from our patient. This phenomenon is commonly
seen on biopsies of relapsed or refractory cases of lymphoma
[9]; however, the loss of CD20 has not been formally
associated with a worse outcome [10]. The IPI score at
diagnosis in our patient was 1 (elevated LDH), implying a
low-riskdiseasewithanestimated5-yearoverallsurvivaland
complete response rate of 73% and 87%, respectively. Our
patient failed to obtain a complete response to RCHOP and
progressed while on active treatment. A rebiopsy showed a
similar histology but with a diﬀerent phenotype that was not
limited to the loss of CD20. Based on the Hans classiﬁcation
[11] our patient presented initially with a CD20-positive
DLBCL of a GC origin (CD10 negative, bcl-6 positive,
MUM-1 negative), but on biopsy of his refractory disease his
phenotypicproﬁleswitchedtoaCD20-negativeNGC(CD10
negative, bcl-6 negative, and MUM-1 positive) DLBCL. A
literature search failed to ﬁnd similar cases in the literature.
Hence, we are unsure of the clinical signiﬁcance of this
immunophenotypical switch but believe it could correlate
with this patient’s aggressive clinical course, despite his
apparent initial low-risk disease.
There is, however, another potential explanation for our
ﬁndings. Our patient could have had 2 diﬀerent clones, the
GConethatrespondedinitiallytoRCHOPandtheNGCone
that was refractory to RCHOP and ﬁnally progressed while
on treatment. The fact that both biopsies were taken from
thesameanatomicalareamakesthispossibility,althoughnot
impossible, less likely. Molecular studies evaluating IgH gene
rearrangements could have been helpful to prove a clonal
relationship between the two processes; unfortunately, the
IgH PCR study at diagnosis was negative while the second
IgH PCR showed one band consistent with the expansion of
a single lymphoid clone.
As a side point, our patient did not receive HAART at
initial DLBCL diagnosis because his CD4+ cell count was
456cells/mm3. Later on, he was started on HAART after his
refractory disease was identiﬁed when his CD4+ cell count
was 309 cells/mm3. It is unclear if the lack of use of HAART
could have played a role in the refractoriness of his disease.
However, few studies have shown that stopping HAART
temporarily whileundergoing chemotherapy is safeand does
not seem to aﬀect survival in patients with HIV-associated
DLBCL [12].
Our case highlights the biological plasticity inherent to
lymphoproliferative disorders, in which spontaneous (i.e.,
Richter’s transformation) and/or therapy-induced (i.e., post
rituximab) changes are not uncommon. We present a patient
withHIV-positiveDLBCLthatbecamerefractorytoRCHOP
despite his apparent low-risk disease, maybe associated to an
immunophenotypical switch from an GC to a NGC proﬁle
or the development of a chemotherapy-refractory clone.
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